TPIP (Treprostinil Palmitil Inhalation Powder)
Pulmonary Arterial Hypertension (PAH)
Key Facts
About Insmed
Insmed is a patient-centric, global biopharma leader with a mission to deliver transformative therapies for serious and rare diseases. The company has achieved significant commercial and clinical milestones, including regulatory approvals and advanced late-stage pipelines, underpinned by a culture consistently recognized as a top employer. Its strategy hinges on deep patient collaboration, a synergistic technology platform spanning drug delivery and small molecules, and a disciplined focus on high-need pulmonary and rare disease markets.
View full company profileAbout Insmed
Insmed is a patient-centric, global biopharma leader with a mission to deliver transformative therapies for serious and rare diseases. The company has achieved significant commercial and clinical milestones, including regulatory approvals and advanced late-stage pipelines, underpinned by a culture consistently recognized as a top employer. Its strategy hinges on deep patient collaboration, a synergistic technology platform spanning drug delivery and small molecules, and a disciplined focus on high-need pulmonary and rare disease markets.
View full company profileTherapeutic Areas
Other Pulmonary Arterial Hypertension (PAH) Drugs
| Drug | Company | Phase |
|---|---|---|
| YUTREPIA™ (treprostinil) inhalation powder | Liquidia | Approved |
| LIQ861 (treprostinil) inhalation powder | Liquidia | Phase 3 |
| L606 (liposomal treprostinil) injection | Liquidia | Preclinical |
| NTP42 | ATXA Therapeutics | Phase 1 |
| Transdermal Treprostinil Prodrug Patch | Corsair Pharma | Pre-clinical |
| Anti-EMAP II monoclonal antibody | Allinaire Therapeutics | Pre-clinical |
| Tiprelestat | tiakis Biotech | Phase 2 |
| Seralutinib | Chiesi | Phase 3 |
| Sotatercept | Merck | Phase 3 |
| Ralinepag | United Therapeutics | Phase 3 |
| Beraprost MR | United Therapeutics | Phase 3 |
| CS1 | Cereno Scientific | Phase II |